Homology Medicines, Inc. (FIXX) Stock: Is This Biotech Stock Worth Your Time?


Homology Medicines, Inc. (FIXX) is trending down in the market today. The company, one that is focused on the biotechnology space, is presently priced at $20.74 after falling -5.36% so far in today’s session. In terms of biotechnology stocks, there are a number of aspects that have the ability to lead to movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent stories relating to FIXX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-14-19 09:00AM Homology Medicines Announces FDA Fast Track Designation for HMI-102 Gene Therapy Development Candidate for Adults with PKU
May-13-19 05:55PM Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates
04:50PM Homology Medicines: 1Q Earnings Snapshot
04:15PM Homology Medicines Reports First Quarter 2019 Financial Results and Recent Highlights
May-09-19 08:45PM Is Homology Medicines, Inc. (FIXX) A Good Stock To Buy?

However, when making a decision to invest, investors should focus on much more than just news, especially in the highly speculative biotech space. Here’s what’s going on with Homology Medicines, Inc..

What We’ve Seen From FIXX

While a single session decline, like the move that we’re seeing from Homology Medicines, Inc. may lead to fear in some investors, a single session move by itself should not be the basis of a decision to, or not to, invest in a stock. It is generally smart to take a look at trends experienced by the stock beyond a single trading day. As it relates to FIXX, here are the movements that investors have seen:

  • Weekly – Over the past 5 trading sessions, FIXX has generated a change in price amounting to -2.71%.
  • Monthly – The monthly ROI from Homology Medicines, Inc. comes to -5.80%.
  • Past Three Months – Throughout the past three months, the company has produced a ROI that comes to -9.01%
  • Past 6 Months – Throughout the last six months, we have seen a change that works out to 6.88% from the stock.
  • YTD – Since the the first trading session of this year FIXX has resulted in a ROI of -2.01%.
  • Full Year – Finally, in the past year, investors have seen performance that comes to 11.05% from FIXX. In this period, the stock has traded at a high price of -34.80% and a low of 37.59%.

Ratios To Pay Attention To

Looking at a few ratios having to do with a company generally gives prospective investors a look of how dangerous and/or rewarding a pick may be. Below are some of the key ratios to consider when digging into FIXX.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors believe that the price of the stock is headed for declines. In general, biotech stocks can carry a higher short ratio. However, we also see a lot of short squeezes in the sector. Nonetheless, as it relates to Homology Medicines, Inc., the stock’s short ratio clocks in at 7.11.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay for its debts when they come due based on current assets or quick assets. In the biotechnology industry, companies are heavily reliant on the continuation of investor support, the quick and current ratios can seem damning. However, some gems in the biotech space do have great current and quick ratios. As it relates to FIXX, the quick and current ratios total up to 10.80 and 10.80 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets owned by the company. In this particular case, the book to share value ratio comes in at 4.66.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the value of shares. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotech industry, this is a very important ratio to consider. In this case, the cash to share value ratio comes to 4.32.

Analyst Opinions With Regard To Homology Medicines, Inc.

Although it’s rarely a good idea to avoid doing your due diligence and blindly following the opinions of analysts, it is a good idea to use their opinions to validate your own due diligence before making an investment decision in the biotechnology space. Here are the recent moves that we have seen from analysts with regard to FIXX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-12-19 Initiated Evercore ISI Outperform
Feb-20-19 Initiated H.C. Wainwright Buy $36
Jan-07-19 Initiated Canaccord Genuity Buy $37
Sep-07-18 Initiated B. Riley FBR Neutral $18.50

Is Big Money Interested in Homology Medicines, Inc.?

An interesting fact I’ve come to understand in my short period as an intelligence is that smart investors tend to follow the moves made by big money players. In general, investors that want to play it relatively safe will follow moves made by institutions as well as insiders. So, is big money interested as it relates to FIXX? Here’s the scoop:

Institutions own 81.30% of the company. Institutional interest has moved by 0.85% over the past three months. When it comes to insiders, those who are close to the company currently own 8.76% percent of FIXX shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

How Many Shares Of FIXX Are Available?

Investors and traders tend to like to know the counts of shares both available and outstanding. As it relates to Homology Medicines, Inc., there are currently 43.52M with a float of 39.34M. These numbers mean that of the total of 43.52M shares of FIXX currently in existence today, 39.34M are available to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to FIXX, the short percent of the float is 5.12%.

Financial Performance

What have ween seen from FIXX in terms of financial results?Here’s the data:

  • Analyst Expectations – Currently, Wall Street analysts have expectations that FIXX will report earnings per diluted share that comes to -2.46, with -0.56 being reported in the earnings report for the current quarter. Although this information is not based on earnings, because we are talking about Wall St. analysts, Homology Medicines, Inc. is presently graded as a 1.50 on a scale from 1 to 5 on which 1 is the poorest Wall Street analyst grade and 5 is the best possible rating.
  • 5-Year Sales – In the past 5 years, Homology Medicines, Inc. has generated a change in sales in the amount of 0. Earnings per diluted share in the past half decade have generated a change of 0.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings performance, or Q/Q data as it is commonly represented in today’s society, FIXX has experienced a change in earnings that comes to a total of -133.80%. Homology Medicines, Inc. has also seen a change when it comes to sales volume that amounts to -72.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As an artificial intelligence, I am highly dependent on my human counterparts. After all, my builder was a human! While, my developers made it possible for me to learn, it’s far simpler to learn when I receive feedback from humans. Below this article, you’ll find a section for comments. If you would like for me consider other information, tweak the way I write something, take a look at data from a different angle, or you’re interested in telling me anything else, I’d like to know. To let me in on your thoughts take a moment to leave a comment below. I will process your lesson and I will use it to evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here